Fox RJ - Search Results

1

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P; RESTORE. Fox RJ, et al. Neurology. 2014 Apr 29;82(17):1491-8. doi: 10.1212/WNL.0000000000000355. Epub 2014 Mar 28. Neurology. 2014. PMID: 24682966 Free PMC article. Clinical Trial.

2

Multiple sclerosis: disease markers accelerate progress.

Fox RJ, Rudick RA. Fox RJ, et al. Lancet Neurol. 2004 Jan;3(1):10. doi: 10.1016/s1474-4422(03)00610-0. Lancet Neurol. 2004. PMID: 14693099 Review. No abstract available.

3

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.

Stüve O, Kita M, Pelletier D, Fox RJ, Stone J, Goodkin DE, Zamvil SS. Stüve O, et al. Among authors: fox rj. Mult Scler. 2004 Jun;10 Suppl 1:S58-61. doi: 10.1191/1352458504ms1032oa. Mult Scler. 2004. PMID: 15218811 Review.

4

Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.

Fox RJ, Bethoux F, Goldman MD, Cohen JA. Fox RJ, et al. Cleve Clin J Med. 2006 Jan;73(1):91-102. doi: 10.3949/ccjm.73.1.91. Cleve Clin J Med. 2006. PMID: 16444920 Free article. Review.

5

Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.

Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H; ACT Investigators. Cohen JA, et al. Among authors: fox rj. Mult Scler. 2008 Apr;14(3):370-82. doi: 10.1177/1352458507083189. Epub 2008 Jan 21. Mult Scler. 2008. PMID: 18208877 Clinical Trial.

6

Is natalizumab overshooting its rebound?

Fox RJ, Kappos L. Fox RJ, et al. Neurology. 2008 Mar 25;70(13 Pt 2):1073-4. doi: 10.1212/01.wnl.0000306415.37679.5a. Neurology. 2008. PMID: 18362270 No abstract available.

7

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.

Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, Waubant E, Gazda S, Fox RJ, Panzara M, Sarkar N, Agarwal S, Smith CH. Bar-Or A, et al. Among authors: fox rj. Ann Neurol. 2008 Mar;63(3):395-400. doi: 10.1002/ana.21363. Ann Neurol. 2008. PMID: 18383069 Clinical Trial.

8

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.

Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA. Jacob A, et al. Among authors: fox rj. Arch Neurol. 2008 Nov;65(11):1443-8. doi: 10.1001/archneur.65.11.noc80069. Epub 2008 Sep 8. Arch Neurol. 2008. PMID: 18779415

9

A preliminary validation study of diffusion tensor imaging as a measure of functional brain injury.

Fox RJ, McColl RW, Lee JC, Frohman T, Sakaie K, Frohman E. Fox RJ, et al. Arch Neurol. 2008 Sep;65(9):1179-84. doi: 10.1001/archneur.65.9.1179. Arch Neurol. 2008. PMID: 18779420

10

Picturing multiple sclerosis: conventional and diffusion tensor imaging.

Fox RJ. Fox RJ. Semin Neurol. 2008 Sep;28(4):453-66. doi: 10.1055/s-0028-1083689. Epub 2008 Oct 8. Semin Neurol. 2008. PMID: 18843574 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

328 results

Search Page